Citizens Financial Group Inc. RI Sells 1,423 Shares of Thermo Fisher Scientific Inc. $TMO

Citizens Financial Group Inc. RI decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,786 shares of the medical research company’s stock after selling 1,423 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Thermo Fisher Scientific were worth $19,065,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $170,000. Raymond James Financial Inc. lifted its position in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after buying an additional 2,262 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 0.4%

Shares of NYSE TMO traded up $2.01 during mid-day trading on Friday, hitting $526.72. The stock had a trading volume of 1,233,008 shares, compared to its average volume of 1,993,707. The firm has a market cap of $195.74 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 2.33 and a beta of 0.87. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The business has a 50 day moving average price of $478.23 and a two-hundred day moving average price of $516.44. Thermo Fisher Scientific Inc. has a 1 year low of $403.36 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. Weiss Ratings lowered Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price for the company. Barclays decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Finally, Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.